Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | THPO | P40225 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15346871 | 0.99 | PTGS2 (0.98) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15347184 | 0.89 | PTGS2 (0.81) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4587819 | 0.89 | PTGS2 (0.79) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL15346938 | 0.88 | PTGS2 (0.83) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL4617859 | 0.88 | PTGS2 (0.83) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL5698670 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL15347026 | 0.87 | PTGS2 (0.77) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL15346898 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1CYP3A4CYP2C9TSHR | |
| SCHEMBL19664982 | 0.87 | PTGS2 (0.98) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL15347199 | 0.87 | PTGS2 (1.00) | PTGS2PTGS1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377289-A4 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | JB CHEMICALS & PHARMACEUTICALS (IN) | 2008-09-10 | — | — | EP | claimed |
| EP-1377289-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. Chemicals & Pharmaceuticals Ltd. (IN) | 2004-01-07 | — | — | EP | claimed |
| WO-2002074235-A2 | HETEROCYCLIC COMPOUNDS FOR THERAPEUTIC USE | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2002-09-26 | — | — | WO | claimed |
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | claimed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | claimed |
| EP-3363435-A1 | ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES | The Ohio State University Research Foundation (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2635274-B1 | ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES | UNIV OHIO STATE RES FOUND (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9079899-B2 | Anti-staphylococcal celecoxib derivatives | THE OHIO STATE UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130289004-A1 | ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-31 | — | — | US | disclosed |
| US-6403629-B2 | 1-(P-(METHYLSULFONAMIDO)PHENYL)-3-TRIFLUOROMETHYL-5-PHENYLPYRA ZOLONE AND DERIVATIVES; ANTIINFLAMMATORY AGENTS | J.B. CHEMICAL AND PHARMACEUTICALS LIMITED (IN) | 2002-06-11 | — | — | US | disclosed |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | J.B. CHEMICALS & PHARMACEUTICALS LIMITED | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289004-A1 | ANTI-STAPHYLOCOCCAL CELECOXIB DERIVATIVES | PTGS1, IL17A, IKBKE | PTGS2 13/4885PTGS1 1/4885CYP1A2 1521/4885 |
| US-20010047023-A1 | New Heterocyclic compounds for therapeutic use | AADAC, NAT1, FPR1 | PTGS2 352/4885PTGS1 94/4885CYP1A2 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.